Company Description

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery.

The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

CervoMed Inc.

Country	United States
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	John Alam

Contact Details

Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States
Phone	617 744 4400
Website	cervomed.com

Stock Details

Ticker Symbol	CRVO
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001053691
ISIN Number	US15713L1098
Employer ID	30-0645032
SIC Code	2834

Key Executives

Name	Position
Dr. John J. Alam M.D.	Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D.	Co-Founder and Director
William Robert Elder J.D.	Chief Financial Officer and General Counsel
Dr. Robert J. Cobuzzi Jr., Ph.D.	Chief Operating Officer and Director
Kelly Blackburn M.H.A.	Senior Vice President of Clinical Development

Latest SEC Filings

Date	Type	Title
Oct 16, 2024	8-K	Current Report
Oct 11, 2024	424B3	Prospectus
Oct 10, 2024	EFFECT	Notice of Effectiveness
Oct 10, 2024	424B3	Prospectus
Oct 9, 2024	EFFECT	Notice of Effectiveness
Oct 3, 2024	S-3	Registration statement under Securities Act of 1933
Oct 3, 2024	POS AM	Post-Effective amendments for registration statement
Oct 3, 2024	8-K	Current Report
Oct 1, 2024	424B3	Prospectus
Oct 1, 2024	8-K	Current Report

View All SEC Filings